In Brief
This article was originally published in The Tan Sheet
Executive Summary
Okla. and Ala. limit PSE sales while Colo. and Hawaii consider NPLEx; Abbott, Biocon team on Indian nutrition R&D; Bunge leaves Solae stake to DuPont; Valeant buys AcneFree; more news In Brief.
You may also be interested in...
In Brief
FTC asked to investigate Claritin ad with “Madagascar” film characters; DSM’s i-Health aces NAD BrainStrong review; regulatory pressure mounts on DMAA; Hawaii joins NPLEx; more news In Brief.
Signs Point To Abbott Joint Venture With India’s Biocon
India-based Biocon’s collaborative research arm Syngene, known for its research partnerships with a large set of global companies, likely will develop products up to a certain stage based on leads Abbott provides. Industry sources say they expect Abbott and Biocon are in advanced discussions.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.